Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarker-guided immunosuppression withdrawal after liver transplantation
2014-004557-14Phase 4Unknown
- Sponsor
- King's College London
- Start
- Dec 2014
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tacrolimus, mycophenolic acid, cyclosporine, mycophenolate mofetil, azathioprine and 2 more in liver transplant (3 arms), sponsored by King's College London. Primary endpoint: Operational tolerance after immunosuppression withdrawal. Status: unknown.
02
Drugs
tacrolimusmycophenolic acidcyclosporinemycophenolate mofetilazathioprine
03
Conditions
liver transplant
Beyond the preview
Go deeper on 2014-004557-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004557-14.